Moscatilin, a bibenzyl derivative from the India orchid Dendrobrium loddigesii, suppresses tumor angiogenesis and growth in vitro and in vivo

Cancer Letters

Volumn 292, Issue 2, 2010, Pages 163-170

  Tsai, An Chi ^a   Pan, Shiow Lin ^a,c   Liao, Cho Hwa ^a   Guh, Jih Hwa ^a   Wang, Shih Wei ^a   Sun, Hui Lung ^a   Liu, Yi Nan ^a   Chen, Chien Chih ^b   Shen, Chien Chang ^b   Chang, Ya Ling ^a   Teng, Che Ming ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Angiogenesis; BFGF; Endothelial cells; Moscatilin; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MOSCATILIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN; BENZYL DERIVATIVE; DENDROPHENOL; FIBROBLAST GROWTH FACTOR 2; PLANT EXTRACT; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DENDROBIUM; DENDROBIUM LODDIGESII; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN UMBILICAL VEIN ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL DIVISION; CELL LINE; CHEMISTRY; DRUG EFFECT; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; VASCULARIZATION;

ANIMALS; BENZYL COMPOUNDS; BLOTTING, WESTERN; CELL DIVISION; CELL LINE; DENDROBIUM; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLANT EXTRACTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77951913859     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.11.020     Document Type: Article

References (35)

1. Folkman J. Angiogenesis. Annu. Rev. Med. 2006, 57:1-18.
2. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Natl. Rev. Drug. Discov. 2007, 6:273-286.
3. Bhat T.A., Singh R.P. Tumor angiogenesis - a potential target in cancer chemoprevention. Food. Chem. Toxicol. 2008, 46:1334-1345.
4. Liu W., Ahmad S.A., Reinmuth N., Shaheen R.M., Jung Y.D., Fan F., Ellis L.M. Endothelial cell survival and apoptosis in the tumor vasculature. Apoptosis 2000, 5:323-328.
5. Gourley M., Williamson J.S. Angiogenesis: new targets for the development of anticancer chemotherapies. Curr. Pharm. Des. 2000, 6:417-439.
6. Eskens F.A. Angiogenesis inhibitors in clinical development; where are we now and where are we going?. Br. J. Cancer 2004, 90:1-7.
7. Munoz-Chapuli R., Quesada A.R., Angel Medina M. Angiogenesis and signal transduction in endothelial cells. Cell. Mol. Life Sci. 2004, 61:2224-2243.
8. Somanath P.R., Razorenova O.V., Chen J., Byzova T.V. Akt1 in endothelial cell and angiogenesis. Cell Cycle 2006, 5:512-518.
9. Jiang B.H., Liu L.Z. AKT signaling in regulating angiogenesis. Curr. Cancer Drug Targets 2008, 8:19-26.
10. Pages G., Milanini J., Richard D.E., Berra E., Gothie E., Vinals F., Pouyssegur J. Signaling angiogenesis via p42/p44 MAP kinase cascade. Ann. NY Acad. Sci. 2000, 902:187-200.
11. Berra E., Milanini J., Richard D.E., Le Gall M., Vinals F., Gothie E., Roux D., Pages G., Pouyssegur J. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem. Pharmacol. 2000, 60:1171-1178.
12. Papapetropoulos A., Garcia-Cardena G., Madri J.A., Sessa W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 1997, 100:3131-3139.
13. Babaei S., Teichert-Kuliszewska K., Monge J.C., Mohamed F., Bendeck M.P., Stewart D.J. Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. Circ. Res. 1998, 82:1007-1015.
14. Cooke J.P. NO and angiogenesis. Atheroscler. Suppl. 2003, 4:53-60.
15. Duda D.G., Fukumura D., Jain R.K. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol. Med. 2004, 10:143-145.
16. Ando A., Yang A., Nambu H., Campochiaro P.A. Blockade of nitric-oxide synthase reduces choroidal neovascularization. Mol. Pharmacol. 2002, 62:539-544.
17. Nishida N., Yano H., Nishida T., Kamura T., Kojiro M. Angiogenesis in cancer. Vasc. Health Risk Manage. 2006, 2:213-219.
18. Pang R.W., Poon R.T. Clinical implications of angiogenesis in cancers. Vasc. Health Risk Manage. 2006, 2:97-108.
19. Rhee J., Hoff P.M. Angiogenesis inhibitors in the treatment of cancer. Expert. Opin. Pharmacother. 2005, 6:1701-1711.
20. Kesisis G., Broxterman H., Giaccone G. Angiogenesis inhibitors. Drug selectivity and target specificity. Curr. Pharm. Des. 2007, 13:2795-2809.
21. Chen C.C., Wu L.G., Ko F.N., Teng C.M. Antiplatelet aggregation principles of Dendrobium loddigesii. J. Natl. Prod. 1994, 57:1271-1274.
22. Ho C.K., Chen C.C. Moscatilin from the orchid Dendrobrium loddigesii is a potential anticancer agent. Cancer Invest. 2003, 21:729-736.
23. Chen T.H., Pan S.L., Guh J.H., Liao C.H., Huang D.Y., Chen C.C., Teng C.M. Moscatilin induces apoptosis in human colorectal cancer cells: a crucial role of c-Jun NH2-terminal protein kinase activation caused by tubulin depolymerization and DNA damage. Clin. Cancer Res. 2008, 14:4250-4258.
24. Liu Y.N., Pan S.L., Peng C.Y., Huang D.Y., Guh J.H., Chen C.C., Shen C.C., Teng C.M. Moscatilin Repressed Lipopolysaccaride-Induced HIF-1alpha accumulation and NF-kappaB Activation in Murine RAW264.7 Cells. Shock 2009.
25. Cross M.J., Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 2001, 22:201-207.
26. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
27. Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7:359-371.
28. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399:601-605.
29. Dimmeler S., Dernbach E., Zeiher A.M. Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett. 2000, 477:258-262.
30. Kostyk S.K., Kourembanas S., Wheeler E.L., Medeiros D., McQuillan L.P., D'Amore P.A., Braunhut S.J. Basic fibroblast growth factor increases nitric oxide synthase production in bovine endothelial cells. Am. J. Physiol. 1995, 269:H1583-H1589.
31. Kaneshiro T., Morioka T., Inamine M., Kinjo T., Arakaki J., Chiba I., Sunagawa N., Suzui M., Yoshimi N. Anthraquinone derivative emodin inhibits tumor-associated angiogenesis through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation. Eur. J. Pharmacol. 2006, 553:46-53.
32. Yang Y.H., Wang Y., Lam K.S., Yau M.H., Cheng K.K., Zhang J., Zhu W., Wu D., Xu A. Suppression of the Raf/MEK/ERK signaling cascade and inhibition of angiogenesis by the carboxyl terminus of angiopoietin-like protein 4. Arterioscler. Thromb. Vasc. Biol. 2008, 28:835-840.
33. Dimmeler S., Zeiher A.M. Akt takes center stage in angiogenesis signaling. Circ. Res. 2000, 86:4-5.
34. Michell B.J., Griffiths J.E., Mitchelhill K.I., Rodriguez-Crespo I., Tiganis T., Bozinovski S., de Montellano P.R., Kemp B.E., Pearson R.B. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr. Biol. 1999, 9:845-848.
35. Cross M.J., Dixelius J., Matsumoto T., Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem. Sci. 2003, 28:488-494.